Label-Free Infrared Spectral Histology of Skin Tissue Part II: Impact of a Lumican-Derived Peptide on Melanoma Growth.

Fiche publication

Date publication

janvier 2020

Journal

Frontiers in cell and developmental biology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BREZILLON Stéphane , Pr SOCKALINGUM Ganesh , Dr BOULAGNON-ROMBI Camille

Tous les auteurs :
Brézillon S, Untereiner V, Mohamed HT, Ahallal E, Proult I, Nizet P, Boulagnon-Rombi C, Sockalingum GD

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32548117

Résumé

Melanoma is the most aggressive type of cutaneous malignancies. In addition to its role as a regulator of extracellular matrix (ECM) integrity, lumican, a small leucine-rich proteoglycan, also exhibits anti-tumor properties in melanoma. This work focuses on the use of infrared spectral imaging (IRSI) and histopathology (IRSH) to study the effect of lumican-derived peptide (L9Mc) on B16F1 melanoma primary tumor growth. Female C57BL/6 mice were injected with B16F1 cells treated with L9Mc ( = 10) or its scrambled peptide ( = 8), and without peptide (control, = 9). The melanoma primary tumors were subjected to histological and IR imaging analysis. In addition, immunohistochemical staining was performed using anti-Ki-67 and anti-cleaved caspase-3 antibodies. The IR images were analyzed by common K-means clustering to obtain high-contrast IRSH that allowed identifying different ECM tissue regions from the epidermis to the tumor area, which correlated well with H&E staining. Furthermore, IRSH showed good correlation with immunostaining data obtained with anti-Ki-67 and anti-cleaved caspase-3 antibodies, whereby the L9Mc peptide inhibited cell proliferation and increased strongly apoptosis of B16F1 cells in this mouse model of melanoma primary tumors.